Prophylaxis and treatment of anaerobic infections following caesarean section with tinidazole.
The purpose of this prospective, double-blind, placebo-controlled study was to clarify the effect of a single intravenous infusion of 500 mg of tinidazole on infections that followed a caesarean section. 80 consecutive caesarean-section patients and thereafter 72 women undergoing non-elective caesarean section were randomly assigned to two groups, each receiving intravenous infusions at cord clamping. In the entire sample the incidence of endometritis/wound infection in the placebo group was 27.3% (21/77) versus 10.7% (8/75) in the tinidazole group (p less than 0.01). In the non-elective caesarean-section group the incidence of endometritis/wound infection was 39.6% (21/53) in the placebo group versus 14.3% (7/49) in the tinidazole group (p less than 0.01). 27 positive bacterial cultures yielded a pure anaerobic growth in 59% (16/27) of cases, of which 87.5% (14/16) were treated successfully with oral tinidazole.
D000328:Adult; D000653:Amniotic Fluid / Q000382:microbiology; D000693:Anaerobiosis; D001424:Bacterial Infections / Q000517:prevention & control*; D002585:Cesarean Section; D004311:Double-Blind Method; D004716:Endometritis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use*; D011247:Pregnancy; D011446:Prospective Studies; D014011:Tinidazole / Q000627:therapeutic use*
D009593:Nitroimidazoles; D014011:Tinidazole